| First Author | Kalinowski D | Year | 2023 |
| Journal | Sci Rep | Volume | 13 |
| Issue | 1 | Pages | 897 |
| PubMed ID | 36650256 | Mgi Jnum | J:332668 |
| Mgi Id | MGI:7428124 | Doi | 10.1038/s41598-023-28069-2 |
| Citation | Kalinowski D, et al. (2023) Dopaminergic and cholinergic modulation of the amygdala is altered in female mice with oestrogen receptor beta deprivation. Sci Rep 13(1):897 |
| abstractText | The amygdala is modulated by dopaminergic and cholinergic neurotransmission, and this modulation is altered in mood disorders. Therefore, this study was designed to evaluate the presence/absence of quantitative alterations in the expression of main dopaminergic and cholinergic markers in the amygdala of mice with oestrogen receptor beta (ERbeta) knock-out which exhibit increased anxiety, using immunohistochemistry and quantitative methods. Such alterations could either contribute to increased anxiety or be a compensatory mechanism for reducing anxiety. The results show that among dopaminergic markers, the expression of tyrosine hydroxylase (TH), dopamine transporter (DAT) and dopamine D(2)-like receptor (DA(2)) is significantly elevated in the amygdala of mice with ERbeta deprivation when compared to matched controls, whereas the content of dopamine D(1)-like receptor (DA(1)) is not altered by ERbeta knock-out. In the case of cholinergic markers, muscarinic acetylcholine type 1 receptor (AChR(M1)) and alpha-7 nicotinic acetylcholine receptor (AChR(alpha7)) display overexpression while the content of acetylcholinesterase (AChE) and vesicular acetylcholine transporter (VAChT) remains unchanged. In conclusion, in the amygdala of ERbeta knock-out female the dopaminergic and cholinergic signalling is altered, however, to determine the exact role of ERbeta in the anxiety-related behaviour further studies are required. |
